Abstract
Cabozantinib Increases Progression–free Survival in Radioiodine–Refractory Differentiated Thyroid Cancer across Tumor Histologies and after Previous Anti–VEGF Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have